Ondine Biomedical (LSE:OBI), which develops non-antibiotic antimicrobial treatments activated by light, said its pivotal Phase 3 LANTERN trial evaluating nasal photodisinfection for the prevention of surgical site infections is close to completion. The study has now enrolled about 93% of its target participants across clinical centres in the United States and Canada, while data integrity, monitoring processes, and endpoint review procedures remain largely on schedule. The trial, involving more than 5,000 patients, represents a major component of the company’s pathway toward U.S. regulatory approval, with top-line results anticipated in spring 2026. Positive findings could reinforce Ondine’s role in infection prevention as healthcare systems confront increasing antibiotic resistance and a significant burden of hospital-acquired infections.
Despite these developments, the company faces notable financial headwinds. While revenue growth has been strong, Ondine has yet to reach profitability or generate consistent positive cash flow. Technical indicators currently point to negative market momentum, and valuation measures remain challenging, contributing to a cautious overall outlook.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company focused on light-activated antimicrobial technology known as photodisinfection, designed to prevent and treat infections, including those caused by multidrug-resistant pathogens. Its CE-marked nasal photodisinfection system, sold as Steriwave outside the United States, has been approved in several countries and is undergoing clinical evaluation in the U.S. The company is also developing additional applications targeting conditions such as chronic sinusitis, ventilator-associated pneumonia, and burn infections.
Leave a Reply